Announcing our joint venture with European partner, Consilium Strategic Communications: Learn More

Westicke Partners IPO Advisory
Strategic Investor Relations
Independent Capital Markets Advice

Mobile Navigation

Westwicke Blog

The Westwicke Blog is designed to deliver information and insights into the ever-changing world of investor relations and the capital markets, with a specific focus on the healthcare industry.

Rebranding? Here’s How to Communicate With Investors

Posted on August 2nd, 2017. Posted by

Rebranding the Right Way

Not long ago I was surprised to discover that a client of mine that had recently completed a rebranding effort had sent out some messaging to investors under its former name. It turns out that the company was still using its old name with some audiences.

In this case, the company had good reasons to hold onto the benefits of its old brand, so it retained it as a subsidiary to its newly named parent company. And that’s not unusual. Many well-known brands or and products are owned by corporate parents you’ve never heard of (just as many well-known corporations have low-profile subsidiaries or product lines).

Continue Reading

MiFID II: New EU Regulations Will Have a Huge Global Impact

Posted on July 25th, 2017. Posted by

MiFID II is a term you are bound to hear more often over the second half of 2017. It is the European Union’s Markets in Financial Instruments Directive II, a financial services regulation in the EU that will unbundle broker/dealer research and corporate access services from execution services. It is scheduled to become effective on January 3, 2018.

As an executive of an American public healthcare company, you might be asking yourself why you need to be aware of a European regulation. The answer: Because many major institutions operate on a global basis, the impact, while initially centered in Europe, will ultimately be felt in all corners of the global financial markets.

Continue Reading

Five Don’ts for an Investor Meeting Over Lunch

Posted on June 14th, 2017. Posted by

Five Don’ts for an Investor Meeting Over Lunch

A lunch meeting with an investor provides the opportunity to interact in a more relaxed atmosphere than what you’ll find in typical investor meetings. It’s a chance to build rapport and get to know the investor better. It’s also a nice opportunity to strengthen your investment thesis by providing color and anecdotes supporting your strategic initiatives.

But just because it’s not a conventional business meeting doesn’t mean it’s risk-free. On the contrary, whether it’s with a potential new investor or an update with an existing investor, these informal situations include plenty of opportunities to make costly mistakes.

Continue Reading

Biotech Investor Relations: Six Burning Questions Answered

Posted on June 7th, 2017. Posted by

Biotech Investor Relations: Six Burning Questions Answered

I have always found it interesting to discover what is on people’s minds in the moment and to delve into what keeps them up at night. So, I thought it would be useful to share the questions I have received recently from a mix of public and private biotech management teams, along with my responses.

Continue Reading

Six Ways to Make the Most of Dinner with a Research Analyst

Posted on May 3rd, 2017. Posted by

Six Ways to Make the Most of Dinner with a Research Analyst

Dining with one of your analysts can be nerve-racking, but it really doesn’t need to be.

Sharing a meal at a restaurant should make for a less formal meeting than one conducted in a boardroom. The mood should prove to be friendlier and less business-like, and conversations rarely venture deep into the numbers.

Over dinner, analysts frequently probe for “color” related to previously disclosed themes to gather the kind of details that can animate their coverage and talking points for investors.

Continue Reading

Investors Make Decisions By Asking These 6 Questions

Posted on April 19th, 2017. Posted by

Investors Make Decisions By Asking These 6 Questions

In the 30-40 minutes that a typical investor meeting lasts, you need to accomplish several critically important goals. You must:

• Provide your audience with the investment merits of your company

• Answer their questions

• Inspire them to do more research into your market opportunity

If you fail to achieve these objectives, if the investor leaves the meeting without sufficient information and inspiration, then you’ve effectively wasted everyone’s time, including your own.

Continue Reading

Six Do’s and Don’ts for Managing Investor Expectations

Posted on April 12th, 2017. Posted by

When it comes to dealing with investors and analysts, what you say can be every bit as important as what you do.

Effective communication can burnish your company’s image and help drive interest in your shares. Conversely, ineffective communication can undermine your reputation and distort even the strongest of investment stories.

To improve the likelihood that you’ll get your communication with investors and analysts right, let’s review some proven do’s and don’ts.

Continue Reading

How to Deal With That One Difficult Research Analyst

Posted on April 5th, 2017. Posted by

In the film “Peter’s Friends,” Rita Rudner’s character, the star of a fictional sitcom, turns to her husband at the airport and laments, “You know what I hate about being a public figure? The public.”

I’m sure many executives running public companies have shared a similar sentiment from time to time.

The good news is that, alongside your trusted investor relations counsel, there is a group of professionals who can act as a barrier between you and the mass of institutional and private investors, namely sell-side research analysts.

Continue Reading

What to Do When An Investor Meeting Goes Awry

Posted on March 22nd, 2017. Posted by

What to Do When An Investor Meeting Goes Awry

Throughout my 23 years as an institutional salesperson, I had the pleasure to host many interesting and successful investor meetings.

Very few of those meetings went badly, because I always made a point to educate the companies I was traveling with in advance of the meeting. My goal was to make sure the management team had a complete background on the investor they were meeting and a deep understanding of that investor’s investment process and philosophy. I even tried to ensure that the management team knew about any investor’s personality quirks so they would not get thrown off their game during the meeting. Investors can sometimes try to intentionally rattle management teams in order to get them to say things they were not planning to say.

Continue Reading

Four Considerations For Your Non-Deal Road Show Strategy

Posted on March 15th, 2017. Posted by

Four Considerations For Your Non-Deal Road Show Strategy

There’s never a better time than the present to chart your investor interaction strategy over the coming months. What investors do you still need to meet with this year – including follow-ups to initial meetings you’ve already held, and meetings with new investors with whom you haven’t yet connected?

Do you have plans for which conferences to attend, new KOLs to contact, or for attracting new sell-side research?

Of course, all of this consideration needs to be prioritized within the context of your company’s upcoming catalysts: clinical trial progress, data readouts, product approvals, product launches, potential financings, growth target bogeys, and other various metrics investors will use to gauge your progress.

Continue Reading

1 2 3 13

Westwicke Enters Partnership with Consilium Strategic Communications

Announcing our exciting new partnership that extends the Westwicke Partners footprint internationally.

LEARN MORE

Our Locations